MR编号 | NL/H/3512/003 |
---|
药品名称 | Dapratis |
---|
活性成分 | - acetylsalicylic acid 100.0 mg
- atorvastatin calcium trihydrate 40.0 mg
- PERINDOPRIL ARGININE 5.0 mg
|
---|
剂型 | Capsule, hard |
---|
上市许可持有人 | Les Laboratoires Servier
50 rue Carnot
92284 Suresnes Cedex
France |
---|
参考成员国 - 产品名称 | Netherlands (NL) |
---|
互认成员国 - 产品名称 | - Bulgaria (BG)
ASAPRILOR 40 mg/5 mg/100 mg - Czechia (CZ)
DAPRATIS 40mg/5mg/100mg tvrdá tobolka - Greece (GR)
DAPRATIS - Hungary (HU)
- Italy (IT)
- Lithuania (LT)
ASAPRILOR 40mg/5mg/100mg kietosios kapsulės - Latvia (LV)
- Portugal (PT)
- Romania (RO)
|
---|
许可日期 | 2017/10/03 |
---|
最近更新日期 | 2018/02/22 |
---|
药物ATC编码 | - C10BX Lipid modifying agents in combination with other drugs
|
---|
申请类型 | - TypeLevel1:Known Active Substance
- TypeLevel2:Additional Strength/Form
- TypeLevel3:Full Dossier Art 8.3(i) Dir 2001/83/EC
- TypeLevel4:Chemical Substance
- TypeLevel5:Prescription Only
|
---|
附件文件下载 | |
---|
市场状态 | Withdrawn(注:已撤市) 撤市原因:1.The company decided to withdraw the application. At the time of withdrawal, the MS considered that the data provided did not allow to conclude on a positive benefit-risk balance as major objections were raised. |
---|